Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ultragenyx Pharma (RARE) Misses Q3 EPS by 1c
November 2, 2017 5:02 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.87), $0.01 worse than the analyst estimate of ($1.86). Revenue for the quarter came in at $198 thousand versus the consensus estimate of $20 thousand.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More